10:19 AM EDT, 10/21/2026 (MT Newswires) -- Merck KGaA (MRK.F), Nvidia (NVD.F), Microsoft (MSF.F) and Denmark-based Dawn Health will explore the use of artificial intelligence in customizing support programs for patients with rare tumors under their latest collaboration. The German science and technology company will work on the design of the new model, Nvidia will leverage its AI technology and services, Microsoft will provide its cloud platform, and Dawn Health will lead product and application development, as well as regulatory processes, according to a Wednesday release. The model will initially focus on desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas, with primary rollout planned across key markets in Europe.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.